HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease - Insights from randomized clinical trials and human genetics

Emilie Westerlin Kjeldsen, Jesper Qvist Thomassen, Ruth Frikke-Schmidt

35 Citationer (Scopus)

Abstract

Through seven decades the inverse association between HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease (ASCVD) has been observed in case-control and prospective cohort studies. This robust inverse association fuelled the enthusiasm towards development of HDL cholesterol increasing drugs, exemplified by the cholesteryl ester transfer protein (CETP) inhibitor trials and the extended-release niacin HPS2-THRIVE trial. These HDL cholesterol increasing trials were launched without conclusive evidence from human genetics, and despite discrepant species dependent evidence from animal studies. Evidence from human genetics and from randomized clinical trials over the last 13 years now point in the direction that concentrations of HDL cholesterol, do not appear to be a viable future path to target therapeutically for prevention of ASCVD. A likely explanation for the strong observational association between low HDL cholesterol and high ASCVD risk is the concomitant inverse association between HDL cholesterol and atherogenic triglyceride-rich lipoproteins. The purpose of the present review is to bring HDL cholesterol increasing trials into a human genetics context exemplified by candidate gene studies of key players in HDL biogenesis as well as by HDL cholesterol related genome-wide association studies.

OriginalsprogEngelsk
Artikelnummer159063
TidsskriftBiochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
Vol/bind1867
Udgave nummer1
ISSN1388-1981
DOI
StatusUdgivet - jan. 2022

Fingeraftryk

Dyk ned i forskningsemnerne om 'HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease - Insights from randomized clinical trials and human genetics'. Sammen danner de et unikt fingeraftryk.

Citationsformater